Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab in Subfoveal CNV Secondary to AMD (PIER)
NCT00090623Phase 3Completed
- Sponsor
- Genentech
- Start
- Aug 2004
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ranibizumab in Age-related macular degeneration (AMD) (3 arms), sponsored by Genentech. Primary endpoint: Mean change from baseline in Best Corrected Visual Acuity at 12 months. Started Aug 2004; status: completed.
02
Drugs
ranibizumab
03
Conditions
Age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT00090623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00090623.